(Reuters) – Novavax Inc on Wednesday entered into a deal with contract drugmaker AGC Biologics to manufacture its experimental COVID-19 vaccine.

An add-on component of Novavax’s vaccine that could help enhance the immune response against the coronavirus would be manufactured by privately held AGC Biologics, the contract drugmaker said.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Saumyadeb Chakrabarty



READ NEWS SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here